{"title":"Capsule Technologies for Disorders of Gut-Brain Interaction: Hope or Hype?","authors":"Braden Kuo","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 8","pages":"478-481"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparative Effectiveness of Risankizumab Versus Ustekinumab in Bio-naive CD Patients: A Real-World Multicenter Retrospective Cohort Study.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7 Suppl 5","pages":"12-13"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Low Remission Recapture After Ustekinumab Dose Optimization in CD: Results of the Randomized Placebo-Controlled Double-Blind REScUE Study.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7 Suppl 5","pages":"14-15"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long-Term Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for CD: Results From the VIVID-2 Open-Label Extension Study.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7 Suppl 5","pages":"17-18"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dual-Targeted Therapy With Risankizumab and Upadacitinib Is Clinically and Biochemically Effective in Medically Complex CD.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7 Suppl 5","pages":"15-16"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
One in 4 patients with endoscopically confirmed quiescent inflammatory bowel disease (IBD) reports persistent gastrointestinal symptoms, which are often compatible with irritable bowel syndrome (IBS). The reporting of these IBS-type symptoms is associated with psychological comorbidity, impaired quality of life, and increased health care utilization. The brain-gut axis, which provides the link between the central nervous system and gastrointestinal tract, may facilitate these relationships. In IBS, dietary manipulation, gut-brain neuromodulators, and brain-gut behavioral therapies may have a beneficial effect on symptom reporting and quality of life. However, evidence supporting their use in patients reporting IBS-type symptoms specifically in IBD is lacking. Despite this, observational studies describing the relationship between mood and inflammatory activity highlight the role of the brain-gut axis in the pathophysiology of IBD. There remains a need for further carefully designed clinical trials of treatments targeting the brain-gut axis in IBD patients reporting IBS-type symptoms, who may be most likely to respond to these therapies. An integrated approach to management, combining treatments targeting inflammatory activity and brain-gut axis dysfunction, has the potential to improve the natural history of symptoms, psychological well-being, and quality of life in this select group of patients with IBD. This article will review the prevalence, impact, etiology, and treatment options for the management of patients with quiescent IBD who report IBS-type symptoms.
{"title":"Irritable Bowel Syndrome in Inflammatory Bowel Disease Patients: Prevalence, Etiology, and Treatment.","authors":"David J Gracie, Alexander C Ford","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>One in 4 patients with endoscopically confirmed quiescent inflammatory bowel disease (IBD) reports persistent gastrointestinal symptoms, which are often compatible with irritable bowel syndrome (IBS). The reporting of these IBS-type symptoms is associated with psychological comorbidity, impaired quality of life, and increased health care utilization. The brain-gut axis, which provides the link between the central nervous system and gastrointestinal tract, may facilitate these relationships. In IBS, dietary manipulation, gut-brain neuromodulators, and brain-gut behavioral therapies may have a beneficial effect on symptom reporting and quality of life. However, evidence supporting their use in patients reporting IBS-type symptoms specifically in IBD is lacking. Despite this, observational studies describing the relationship between mood and inflammatory activity highlight the role of the brain-gut axis in the pathophysiology of IBD. There remains a need for further carefully designed clinical trials of treatments targeting the brain-gut axis in IBD patients reporting IBS-type symptoms, who may be most likely to respond to these therapies. An integrated approach to management, combining treatments targeting inflammatory activity and brain-gut axis dysfunction, has the potential to improve the natural history of symptoms, psychological well-being, and quality of life in this select group of patients with IBD. This article will review the prevalence, impact, etiology, and treatment options for the management of patients with quiescent IBD who report IBS-type symptoms.</p>","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7","pages":"415-423"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Patient-Provider Conversation About IBS-C Treatment With Tenapanor.","authors":"Christina Hanson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7","pages":"454-455"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploring Irritable Bowel Syndrome Symptoms in Patients With Inflammatory Bowel Disease.","authors":"Gary R Lichtenstein","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7","pages":"407"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Checkpoint Inhibitor Combinations for Hepatocellular Carcinoma Treatment.","authors":"Laura M Kulik","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7","pages":"456-458"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号